<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">PLoS</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PMEDICINE-D-11-00489</article-id><article-id pub-id-type="doi">10.1371/journal.pmed.1001092</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Genetics</subject>
          </subj-group>
          <subj-group>
            <subject>Immunology</subject>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Clinical genetics</subject>
            <subj-group>
              <subject>Personalized medicine</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Drugs and devices</subject>
            <subj-group>
              <subject>Pharmacogenetics</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Infectious diseases</subject>
            <subj-group>
              <subject>Gastrointestinal infections</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Genetics and Genomics</subject>
          <subject>Immunology</subject>
          <subject>Infectious Diseases</subject>
          <subject>Pharmacology</subject>
        </subj-group>
      </article-categories><title-group><article-title><italic>IL28B</italic>, <italic>HLA-C</italic>, and <italic>KIR</italic> Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study</article-title><alt-title alt-title-type="running-head">Prediction of Control of HCV</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Suppiah</surname>
            <given-names>Vijayaprakash</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Gaudieri</surname>
            <given-names>Silvana</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Armstrong</surname>
            <given-names>Nicola J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>O'Connor</surname>
            <given-names>Kate S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Berg</surname>
            <given-names>Thomas</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Weltman</surname>
            <given-names>Martin</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Abate</surname>
            <given-names>Maria Lorena</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Spengler</surname>
            <given-names>Ulrich</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">
            <sup>10</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Bassendine</surname>
            <given-names>Margaret</given-names>
          </name>
          <xref ref-type="aff" rid="aff11">
            <sup>11</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Dore</surname>
            <given-names>Gregory J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff12">
            <sup>12</sup>
          </xref>
          <xref ref-type="aff" rid="aff13">
            <sup>13</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Irving</surname>
            <given-names>William L.</given-names>
          </name>
          <xref ref-type="aff" rid="aff14">
            <sup>14</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Powell</surname>
            <given-names>Elizabeth</given-names>
          </name>
          <xref ref-type="aff" rid="aff15">
            <sup>15</sup>
          </xref>
          <xref ref-type="aff" rid="aff16">
            <sup>16</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Hellard</surname>
            <given-names>Margaret</given-names>
          </name>
          <xref ref-type="aff" rid="aff17">
            <sup>17</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Riordan</surname>
            <given-names>Stephen</given-names>
          </name>
          <xref ref-type="aff" rid="aff18">
            <sup>18</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Matthews</surname>
            <given-names>Gail</given-names>
          </name>
          <xref ref-type="aff" rid="aff12">
            <sup>12</sup>
          </xref>
          <xref ref-type="aff" rid="aff13">
            <sup>13</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Sheridan</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="aff11">
            <sup>11</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Nattermann</surname>
            <given-names>Jacob</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">
            <sup>10</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Smedile</surname>
            <given-names>Antonina</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">
            <sup>9</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>MÃ¼ller</surname>
            <given-names>Tobias</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <xref ref-type="aff" rid="aff7">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Hammond</surname>
            <given-names>Emma</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Dunn</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Negro</surname>
            <given-names>Francesco</given-names>
          </name>
          <xref ref-type="aff" rid="aff19">
            <sup>19</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Bochud</surname>
            <given-names>Pierre-Yves</given-names>
          </name>
          <xref ref-type="aff" rid="aff19">
            <sup>19</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Mallal</surname>
            <given-names>Simon</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Ahlenstiel</surname>
            <given-names>Golo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Stewart</surname>
            <given-names>Graeme J.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>George</surname>
            <given-names>Jacob</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Booth</surname>
            <given-names>David R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <collab xlink:type="simple">for the International Hepatitis C Genetics Consortium (IHCGC)</collab>
          <xref ref-type="fn" rid="fn1">
            <sup>Â¶</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Sydney, Australia</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Institute for Immunology and Allergy Research, Westmead Millennium Institute, University of Sydney, Sydney, Australia</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>Institute for Infectious Diseases, Murdoch University, Perth, Australia</addr-line>       </aff><aff id="aff4"><label>4</label><addr-line>Cancer Research Program, Garvan Institute for Medical Research, University of New South Wales, Sydney, Australia</addr-line>       </aff><aff id="aff5"><label>5</label><addr-line>School of Mathematics and Statistics, University of New South Wales, Sydney, Australia</addr-line>       </aff><aff id="aff6"><label>6</label><addr-line>Medizinische Klinik m.S. Hepatologie und Gastroenterologie, CharitÃ©, Campus Virchow-Klinikum, UniversitÃ¤tsmedizin Berlin, Germany</addr-line>       </aff><aff id="aff7"><label>7</label><addr-line>Department of Hepatology, Clinic for Gastroenterology and Rheumatology, University Clinic Leipzig, Leipzig, Germany</addr-line>       </aff><aff id="aff8"><label>8</label><addr-line>Department of Gastroenterology and Hepatology, Nepean Hospital, Sydney, Australia</addr-line>       </aff><aff id="aff9"><label>9</label><addr-line>Liver Physiopathology Lab, Department of Internal Medicine, University of Turin, Turin, Italy</addr-line>       </aff><aff id="aff10"><label>10</label><addr-line>Department of Internal Medicine I, University of Bonn, Bonn, Germany</addr-line>       </aff><aff id="aff11"><label>11</label><addr-line>Liver Research Group, Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom</addr-line>       </aff><aff id="aff12"><label>12</label><addr-line>National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia</addr-line>       </aff><aff id="aff13"><label>13</label><addr-line>St Vincent's Hospital, Sydney, Australia</addr-line>       </aff><aff id="aff14"><label>14</label><addr-line>NIHR Biomedical Research Unit in Gastroenterology and the Liver, University of Nottingham, Nottingham, United Kingdom</addr-line>       </aff><aff id="aff15"><label>15</label><addr-line>Princess Alexandra Hospital, Department of Gastroenterology and Hepatology, Woolloongabba</addr-line>       </aff><aff id="aff16"><label>16</label><addr-line>The University of Queensland, School of Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia</addr-line>       </aff><aff id="aff17"><label>17</label><addr-line>Burnet Institute, Commercial Road, Melbourne, Victoria, Australia</addr-line>       </aff><aff id="aff18"><label>18</label><addr-line>Gastrointestinal and Liver Unit, Prince of Wales Hospital and University of New South Wales, Sydney, Australia</addr-line>       </aff><aff id="aff19"><label>19</label><addr-line>Divisions of Gastroenterology, Hepatology, and Clinical Pathology, University Hospitals Geneva, Switzerland</addr-line>       </aff><contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Klenerman</surname>
            <given-names>Paul</given-names>
          </name>
          <role>Academic Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group><aff id="edit1">University of Oxford, United Kingdom</aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">david_booth@wmi.usyd.edu.au</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: VS GS JG DB. Performed the experiments: VS SG EH DD DB. Analyzed the data: VS NA GA GS JG DB. Contributed reagents/materials/analysis tools: VS SG NA KO TB MW MA US MB GD WI EP MH SR GM DS JN AS TM EH DD FN PB SM GA GS JG DB. Wrote the first draft of the manuscript: DB. Contributed to the writing of the manuscript: VS SG NA KO TB MW MA US MB GD WI EP MH SR GM DS JN AS TM EH DD FN PB SM GA GS JG DB. <ext-link ext-link-type="uri" xlink:href="http://www.icmje.org/" xlink:type="simple">ICMJE</ext-link> criteria for authorship read and met: VS SG NA KO TB MW MA US MB GD WI EP MH SR GM DS JN AS TM EH DD FN PB SM GA GS JG DB. Agree with manuscript results and conclusions: VS SG NA KO TB MW MA US MB GD WI EP MH SR GM DS JN AS TM EH DD FN PB SM GA GS JG DB. Enrolled patients: US TB MW MA US MB GD WI EP MH SR GM DS JN AS TM GA JG. Statistical authors: NA VS DB. Obtained funding: JG GS DB.</p>
        </fn>
        <fn fn-type="other" id="fn1">
          <p>Â¶ Contributing members of the International Hepatitis C Genetics Consortium (IHCGC) are listed in the Acknowledgments.</p>
        </fn>
      <fn fn-type="conflict">
        <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <month>9</month>
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>13</day>
        <month>9</month>
        <year>2011</year>
      </pub-date><volume>8</volume><issue>9</issue><elocation-id>e1001092</elocation-id><history>
        <date date-type="received">
          <day>3</day>
          <month>3</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>8</month>
          <year>2011</year>
        </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Suppiah et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract abstract-type="toc">
        <p>Vijayaprakash Suppiah and colleagues show that genotyping hepatitis C patients for the <italic>IL28B</italic>, <italic>HLA-C</italic>, and <italic>KIR</italic> genes improves the ability to predict whether or not patients will respond to antiviral treatment.</p>
      </abstract><abstract>
        <sec>
          <title>Background</title>
          <p>To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%â50% of patients. Interleukin 28B (<italic>IL28B</italic>) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined effect of variants of <italic>IL28B</italic> with human leukocyte antigen C (<italic>HLA-C</italic>), and its ligands the killer immunoglobulin-like receptors (<italic>KIR</italic>), which have previously been implicated in HCV viral control.</p>
        </sec>
        <sec>
          <title>Methods and Findings</title>
          <p>We genotyped chronic hepatitis C (CHC) genotype 1 patients with PegIFN/R treatment-induced clearance (<italic>n</italic>â=â417) and treatment failure (<italic>n</italic>â=â493), and 234 individuals with spontaneous clearance, for <italic>HLA-C</italic> C1 versus C2, presence of inhibitory and activating <italic>KIR</italic> genes, and two <italic>IL28B</italic> SNPs, rs8099917 and rs12979860. All individuals were Europeans or of European descent. <italic>IL28B</italic> SNP rs8099917 âGâ was associated with absence of treatment-induced clearance (odds ratio [OR] 2.19, <italic>p</italic>â=â1.27Ã10<sup>â8</sup>, 1.67â2.88) and absence of spontaneous clearance (OR 3.83, <italic>p</italic>â=â1.71Ã10<sup>â14</sup>, 2.67â5.48) of HCV, as was rs12979860, with slightly lower ORs. The <italic>HLA-C</italic> C2C2 genotype was also over-represented in patients who failed treatment (OR 1.52, <italic>p</italic>â=â0.024, 1.05â2.20), but was not associated with spontaneous clearance. Prediction of treatment failure improved from 66% with <italic>IL28B</italic> to 80% using both genes in this cohort (OR 3.78, <italic>p</italic>â=â8.83Ã10<sup>â6</sup>, 2.03â7.04). There was evidence that <italic>KIR2DL3</italic> and <italic>KIR2DS2</italic> carriage also altered HCV treatment response in combination with <italic>HLA-C</italic> and <italic>IL28B</italic>.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Genotyping for <italic>IL28B</italic>, <italic>HLA-C</italic>, and <italic>KIR</italic> genes improves prediction of HCV treatment response. These findings support a role for natural killer (NK) cell activation in PegIFN/R treatment-induced clearance, partially mediated by <italic>IL28B</italic>.</p>
        </sec>
        <sec>
          <title/>
          <p>
            <italic>Please see later in the article for the Editors' Summary</italic>
          </p>
        </sec>
      </abstract><abstract abstract-type="editor">
        <title>Editors' Summary</title>
        <sec id="s5a1">
          <title>Background</title>
          <p>About 170 million people harbor long-term (chronic) infections with the hepatitis C virus (HCV) and 3â4 million people are newly infected with the virus every year. HCVâa leading cause of chronic hepatitis (inflammation of the liver)âis spread though contact with infected blood. Transmission can occur during medical procedures (for example, transfusions with unscreened blood or reuse of inadequately sterilized medical instruments) but in developed countries, where donated blood is routinely screened for HCV, the most common transmission route is needle-sharing among intravenous drug users. HCV infection can cause a short-lived illness characterized by tiredness and jaundice (yellow skin and eyes) but 70%â80% of newly infected people progress to a symptom-free, chronic infection that can eventually cause liver cirrhosis (scarring) and liver cancer. HCV infections can be treated with a combination of two drugsâpegylated interferon-alpha and ribavirin (PegIFN/R). However, PegIFN/R is expensive, causes unpleasant side-effects, and is ineffective in about half of people infected with HCV genotype 1, the commonest HCV strain.</p>
        </sec>
        <sec id="s5a2">
          <title>Why Was This Study Done?</title>
          <p>It would be extremely helpful to be able to identify which patients will respond to PegIFN/R before starting treatment. An individual's genetic make-up plays a key role in the safety and effectiveness of drugs. Thus, pharmacogenomicsâthe study of how genetic variants affects the body's response to drugsâhas the potential to alter the clinical management of many diseases by allowing clinicians to provide individually tailored drug treatments. In 2009, scientists reported that certain single nucleotide polymorphisms (SNPs, a type of genetic variant) lying near the <italic>IL28B</italic> gene (which encodes an immune system protein made in response to viral infections) strongly influence treatment outcomes and spontaneous clearance in HCV-infected people. This discovery is now being used to predict treatment responses to PegIFN/R in clinical practice but genotyping (analysis of variants of) <italic>IL28B</italic> only correctly predicts treatment failure two-thirds of the time. Here, the researchers investigate whether genotyping two additional regions of the genomeâthe <italic>HLA-C</italic> and <italic>KIR</italic> gene lociâcan improve the predictive value of <italic>IL28B</italic> genotyping. Human leukocyte antigen C (HLA-C) and the killer immunoglobulin-like receptors (KIRs) are interacting proteins that have been implicated in HCV viral control.</p>
        </sec>
        <sec id="s5a3">
          <title>What Did the Researchers Do and Find?</title>
          <p>The researchers genotyped 417 patients chronically infected with HCV genotype 1 whose infection had been cleared by PegIFN/R treatment, 493 patients whose infection had not responded to treatment, and 234 patients whose infection had cleared spontaneously for two <italic>HLA-C</italic> variants (C1 and C2), the presence of several KIR genes (individuals carry different combinations of KIR genes), and two <italic>IL28B</italic> SNPs (rs8099917 and rs12979860). Carriage of âvariantsâ of either <italic>IL28B</italic> SNP was associated with absence of treatment-induced clearance and absence of spontaneous clearance. That is, these variant SNPs were found more often in patients who did not respond to treatment than in those who did respond, and more often in patients who did not have spontaneous clearance of their infection than those who did. The HLA-C C2C2 genotype (there are two copies of most genes in the genome) was also more common in patients who failed treatment than in those who responded but was not associated with spontaneous clearance. The rate of correct prediction of treatment failure increased from 66% with <italic>IL28B</italic> genotyping alone to 80% with combined <italic>IL28B</italic> and <italic>HLA-C</italic> genotyping. Finally, carriage of specific <italic>KIR</italic> genes in combination with specific <italic>HLA-C</italic> and <italic>IL28B</italic> variants was also associated with an altered HCV treatment response.</p>
        </sec>
        <sec id="s5a4">
          <title>What Do These Findings Mean?</title>
          <p>These findings show that the addition of <italic>HCL-C</italic> and <italic>KIR</italic> genotyping to <italic>IL28B</italic> genotyping improved the prediction of HCV treatment response in the patients investigated in this study. Because all these patients were European or of European descent, these findings need confirming in people of other ethnic backgrounds. They also need confirming in other groups of Europeans before being used in a clinical setting. However, the discovery that the addition of <italic>HLA-C</italic> genotyping to <italic>IL28B</italic> genotyping raises the rate of correct prediction of PegIFN/R treatment failure to 80% is extremely promising and should improve the clinical management of patients infected with HCV genotype 1. In addition, these results provide new insights into how PegIFN/R clears HCV infections that may lead to improved therapies in the future.</p>
        </sec>
        <sec id="s5a5">
          <title>Additional Information</title>
          <p>Please access these websites via the online version of this summary at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1001092" xlink:type="simple">http://dx.doi.org/10.1371/journal.pmed.1001092</ext-link>.</p>
          <list list-type="bullet">
            <list-item>
              <p>The World Health Organization provides detailed information about <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs164/en/index.html" xlink:type="simple">hepatitis C</ext-link> (in several languages)</p>
            </list-item>
            <list-item>
              <p>The US Centers for Disease Control and Prevention provides information on <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/hepatitis/ChooseC.htm" xlink:type="simple">hepatitis C</ext-link> for the public and for health professionals (information is also available in Spanish)</p>
            </list-item>
            <list-item>
              <p>The US National Institute of Diabetes and Digestive and Kidney Diseases provides basic information on <ext-link ext-link-type="uri" xlink:href="http://digestive.niddk.nih.gov/ddiseases/pubs/hepc_ez" xlink:type="simple">hepatitis C</ext-link> (in English and Spanish)</p>
            </list-item>
            <list-item>
              <p>The <ext-link ext-link-type="uri" xlink:href="http://www.hepctrust.org.uk/" xlink:type="simple">Hepatitis C Trust</ext-link> is a patient-led, patient-run UK charity that provides detailed information about hepatitis C and support for patients and their families; a selection of <ext-link ext-link-type="uri" xlink:href="http://www.hepctrust.org.uk/Get+Involved/Personal+Stories/" xlink:type="simple">personal stories</ext-link> about patients' experiences with hepatitis C is available, including <ext-link ext-link-type="uri" xlink:href="http://www.hepctrust.org.uk/Get+Involved/Personal+Stories/Phils+treatment+story" xlink:type="simple">Phil's treatment story</ext-link>, which details the ups and downs of treatment with PegIFN/R</p>
            </list-item>
            <list-item>
              <p>MedlinePlus provides links to further resources on <ext-link ext-link-type="uri" xlink:href="http://www.nlm.nih.gov/medlineplus/hepatitisc.html" xlink:type="simple">hepatitis C</ext-link></p>
            </list-item>
            <list-item>
              <p>The Human Genome Project provides information about <ext-link ext-link-type="uri" xlink:href="http://www.ornl.gov/sci/techresources/Human_Genome/medicine/medicine.shtml" xlink:type="simple">medicine and the new genetics</ext-link>, including a primer on <ext-link ext-link-type="uri" xlink:href="http://www.ornl.gov/sci/techresources/Human_Genome/medicine/pharma.shtml" xlink:type="simple">pharmacogenomics</ext-link></p>
            </list-item>
          </list>
        </sec>
      </abstract><funding-group><funding-statement>VS, DB, GS, and JG were supported by Australian Research Council Roche Linkage Project grant LPO0990067 and the Robert W. Storr Bequest to the Sydney Clinical School, University of Sydney. GD is supported by an Australian National Health and Medical Research Council Practitioner Fellowship. TB is supported by the German Competence Network for Viral Hepatitis (Hep-Net), funded by the German Ministry of Education and Research (BMBF, Grant No. 01 KI 0437, Genetic host factors in viral hepatitis and Genetic Epidemiology Group in viral hepatitis) and by the EU-Vigilance network of excellence combating viral resistance (VIRGIL, Projekt No. LSHM-CT-2004-503359) as well as by the BMBF Project: Host and viral determinants for susceptibility and resistance to hepatitis C virus infection (Grant No. 01KI0787, Project B). DS and MB (Newcastle University, UK) are funded by a Medical Research Council UK project grant G0502028. JN was supported by BMBF (German Ministry for Science and Education) [grant no. 01KI0791] and H.W. and J. Hector Foundation [grant no. M42]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
        <page-count count="8"/>
      </counts></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Studies of human genetics have been expected to alter clinical management for many diseases, including infectious diseases. Yet, to date, there are few examples of the use of such information in routine clinical practice. One of the most promising examples, identified in genome-wide analyses, is used to predict response to treatment for hepatitis C, based on a single genetic variant.</p>
      <p>Only 20%â30% of the â¼170 million people infected with the hepatitis C virus (HCV) recover spontaneously; the remainder develop chronic infection <xref ref-type="bibr" rid="pmed.1001092-Micallef1">[1]</xref> with a risk for developing cirrhosis, liver failure, and hepatocellular carcinoma <xref ref-type="bibr" rid="pmed.1001092-Hoofnagle1">[2]</xref>. Current standard of care with pegylated interferon-alpha and ribavirin (PegIFN/R) achieves a sustained virological response (SVR) (HCV RNA undetectable 6 mo post cessation of therapy) in 40%â50% of those infected with the most common viral genotype, type 1, after 48 wk <xref ref-type="bibr" rid="pmed.1001092-Feld1">[3]</xref>. Treatment is expensive and is associated with numerous side effects, which sometimes require dose reduction and premature treatment cessation, thus increasing the risk of treatment failure. Host genotyping studies have the potential to identify genes and therefore pathogenic processes important in viral clearance, enabling a rational approach to design new drugs, and to identify patients who will most likely respond to current and new treatments.</p>
      <p>We and others previously used genome-wide association studies (GWAS) to identify SNPs in the genetic region encoding <italic>IL28B</italic>, which strongly influences treatment outcome <xref ref-type="bibr" rid="pmed.1001092-Ge1">[4]</xref>â<xref ref-type="bibr" rid="pmed.1001092-Tanaka1">[6]</xref> and spontaneous clearance <xref ref-type="bibr" rid="pmed.1001092-Thomas1">[7]</xref>. Other genes associated with drug response have not yet been identified in GWAS with genome-wide significance. Variants in linkage with <italic>IL28B</italic> allow prediction of up to 64% for failure to clear virus during therapy in cross-sectional cohorts <xref ref-type="bibr" rid="pmed.1001092-Suppiah1">[5]</xref>. The minor allele of SNP rs8099917 tags the nonresponse haplotype in Asians and Caucasians, but not in African Americans. The minor allele of SNP rs12979860 is on this haplotype in all ethnic groups, and on other less significant haplotypes, so is used where African Americans are in the patient cohort <xref ref-type="bibr" rid="pmed.1001092-Afdhal1">[8]</xref>.</p>
      <p>GWAS are dependent on SNPs tagging associated genetic variants and cannot measure interactions because of the high statistical penalty for multiple comparisons. Human leukocyte antigen (HLA) and killer cell immunoglobulin-like receptors (KIR) are highly polymorphic genetic loci whose gene proteins interact with each other and for which proxy SNPs for their major variants have yet to be identified. HLA-C molecules present ligands for KIR2DL receptors, with a functionally relevant dimorphism determining KIR specificity: <italic>HLA-C</italic> group 1 (HLA-C1) alleles, identified by Ser77/Asp80 of the HLA-C alpha 1 domain, are ligands for the inhibitory receptors KIR2DL2 and KIR2DL3 and the activating receptor KIR2DS2 <xref ref-type="bibr" rid="pmed.1001092-Colonna1">[9]</xref>,<xref ref-type="bibr" rid="pmed.1001092-Wagtmann1">[10]</xref>. <italic>HLA-C</italic> group 2 (<italic>HLA-C2</italic>) alleles, identified by Asp77/Lys80, are recognized by inhibitory KIR2DL1 and activating KIR2DS1 <xref ref-type="bibr" rid="pmed.1001092-Colonna1">[9]</xref>â<xref ref-type="bibr" rid="pmed.1001092-Sato1">[12]</xref>. KIR2DL3 and its ligand, HLA-C1 has been associated with an increased likelihood of spontaneous <xref ref-type="bibr" rid="pmed.1001092-Khakoo1">[13]</xref>â<xref ref-type="bibr" rid="pmed.1001092-VidalCastineira1">[15]</xref>, and treatment-induced HCV clearance <xref ref-type="bibr" rid="pmed.1001092-Knapp1">[14]</xref>,<xref ref-type="bibr" rid="pmed.1001092-VidalCastineira1">[15]</xref>. This association is attributed to differential natural killer (NK) cell activation and function in the context of this KIR/HLA interaction <xref ref-type="bibr" rid="pmed.1001092-Ahlenstiel1">[16]</xref>. SNPs from the <italic>HLA-C</italic> coding regions showed weak associations with SVR in our original GWAS <xref ref-type="bibr" rid="pmed.1001092-Suppiah1">[5]</xref>.</p>
      <p>The current study specifically addresses whether the <italic>IL28B</italic> and <italic>KIR/HLA-C</italic> gene loci have separate, additive, or interactive effects on HCV clearance (spontaneous or treatment induced). This information is essential to better understand the role of <italic>IL28B</italic> during HCV infection, to better predict response to therapy, and potentially to allow better selection of patients for treatment.</p>
    </sec>
    <sec id="s2" sec-type="methods">
      <title>Methods</title>
      <sec id="s2a">
        <title>Ethics Statement and Study Participants</title>
        <p>Ethical approval was obtained from the Human Research Ethics Committees of Sydney West Area Health Service and the University of Sydney. All other sites had ethical approval from their respective ethics committees. Written informed consent was obtained from all participants. Characteristics of each cohort are shown in <xref ref-type="table" rid="pmed-1001092-t001">Table 1</xref>. All treated patients were infected with genotype 1, received PegIFN/R, and had virological response determined 6 mo after completion of therapy. The diagnosis of chronic hepatitis C (CHC) was based on appropriate serology and presence of HCV RNA. All SVRs and non-SVR cases received therapy for 48 wk except when HCV RNA was present with a &lt;2 log drop in HCV RNA level after 12-wk therapy. Patients were excluded if they had been coinfected with either hepatitis B virus or HIV or if they were not of European descent.</p>
        <table-wrap id="pmed-1001092-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001092.t001</object-id><label>Table 1</label><caption>
            <title>Demographic characteristics for chronic hepatitis C patients after therapy, and for those participants with spontaneous virus clearance of HCV included in this study.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pmed-1001092-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.t001" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Demographic Factors<xref ref-type="table-fn" rid="nt101">a</xref></td>
                <td align="left" colspan="2" rowspan="1">Australian Cohort (<italic>n</italic>â=â312)</td>
                <td align="left" colspan="2" rowspan="1">Berlin Cohort (<italic>n</italic>â=â310)</td>
                <td align="left" colspan="2" rowspan="1">Newcastle, UK Cohort (<italic>n</italic>â=â69)</td>
                <td align="left" colspan="2" rowspan="1">Bonn Cohort (<italic>n</italic>â=â57)</td>
                <td align="left" colspan="2" rowspan="1">Trent, UK Cohort (<italic>n</italic>â=â48)</td>
                <td align="left" colspan="2" rowspan="1">Turin Cohort (<italic>n</italic>â=â114)</td>
                <td align="left" colspan="2" rowspan="1">Total Cohort (<italic>n</italic>â=â910)</td>
                <td align="left" colspan="1" rowspan="1">Participants with spontaneous virus clearance (<italic>n</italic>â=â234)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">SVR (<italic>n</italic>â=â130)</td>
                <td align="left" colspan="1" rowspan="1">NSVR (<italic>n</italic>â=â182)</td>
                <td align="left" colspan="1" rowspan="1">SVR (<italic>n</italic>â=â150)</td>
                <td align="left" colspan="1" rowspan="1">NSVR (<italic>n</italic>â=â160)</td>
                <td align="left" colspan="1" rowspan="1">SVR (<italic>n</italic>â=â31)</td>
                <td align="left" colspan="1" rowspan="1">NSVR (<italic>n</italic>â=â38)</td>
                <td align="left" colspan="1" rowspan="1">SVR (<italic>n</italic>â=â26)</td>
                <td align="left" colspan="1" rowspan="1">NSVR (<italic>n</italic>â=â31)</td>
                <td align="left" colspan="1" rowspan="1">SVR (<italic>n</italic>â=â22)</td>
                <td align="left" colspan="1" rowspan="1">NSVR (<italic>n</italic>â=â26)</td>
                <td align="left" colspan="1" rowspan="1">SVR (<italic>n</italic>â=â58)</td>
                <td align="left" colspan="1" rowspan="1">NSVR (<italic>n</italic>â=â56)</td>
                <td align="left" colspan="1" rowspan="1">SVR (<italic>n</italic>â=â417)</td>
                <td align="left" colspan="1" rowspan="1">NSVR (<italic>n</italic>â=â493)</td>
                <td align="left" colspan="1" rowspan="1"/>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">Age (y)</td>
                <td align="left" colspan="1" rowspan="1">40.0 (9.6)</td>
                <td align="left" colspan="1" rowspan="1">44.5 (7.1)</td>
                <td align="left" colspan="1" rowspan="1">41.0 (10.5)</td>
                <td align="left" colspan="1" rowspan="1">46.7 (10.3)</td>
                <td align="left" colspan="1" rowspan="1">38.2 (11.8)</td>
                <td align="left" colspan="1" rowspan="1">46.0 (12.0)</td>
                <td align="left" colspan="1" rowspan="1">44.7 (12.9)</td>
                <td align="left" colspan="1" rowspan="1">50.8 (10.9)</td>
                <td align="left" colspan="1" rowspan="1">39.8 (9.8)</td>
                <td align="left" colspan="1" rowspan="1">45.7 (7.9)</td>
                <td align="left" colspan="1" rowspan="1">43.3 (13.1)</td>
                <td align="left" colspan="1" rowspan="1">45.1 (10.0)</td>
                <td align="left" colspan="1" rowspan="1">40.9 (10.8)</td>
                <td align="left" colspan="1" rowspan="1">45.7<xref ref-type="table-fn" rid="nt102">b</xref> (9.3)</td>
                <td align="left" colspan="1" rowspan="1">NA</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Gender (%)</td>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Females</td>
                <td align="left" colspan="1" rowspan="1">52 (40.0)</td>
                <td align="left" colspan="1" rowspan="1">42<xref ref-type="table-fn" rid="nt102">b</xref> (23.1)</td>
                <td align="left" colspan="1" rowspan="1">79 (52.7)</td>
                <td align="left" colspan="1" rowspan="1">69 (43.1)</td>
                <td align="left" colspan="1" rowspan="1">9 (29.0)</td>
                <td align="left" colspan="1" rowspan="1">10 (26.3)</td>
                <td align="left" colspan="1" rowspan="1">11 (42.3)</td>
                <td align="left" colspan="1" rowspan="1">11 (35.5)</td>
                <td align="left" colspan="1" rowspan="1">6 (27.3)</td>
                <td align="left" colspan="1" rowspan="1">5 (19.2)</td>
                <td align="left" colspan="1" rowspan="1">28 (48.3)</td>
                <td align="left" colspan="1" rowspan="1">19 (33.9)</td>
                <td align="left" colspan="1" rowspan="1">185 (44.4)</td>
                <td align="left" colspan="1" rowspan="1">156<xref ref-type="table-fn" rid="nt102">b</xref> (31.6)</td>
                <td align="left" colspan="1" rowspan="1">111 (47.4)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Males</td>
                <td align="left" colspan="1" rowspan="1">78 (60.0)</td>
                <td align="left" colspan="1" rowspan="1">140 (76.9)</td>
                <td align="left" colspan="1" rowspan="1">71 (47.3)</td>
                <td align="left" colspan="1" rowspan="1">91 (55.9)</td>
                <td align="left" colspan="1" rowspan="1">22 (71.0)</td>
                <td align="left" colspan="1" rowspan="1">28 (73.7)</td>
                <td align="left" colspan="1" rowspan="1">15 (57.7)</td>
                <td align="left" colspan="1" rowspan="1">20 (64.5)</td>
                <td align="left" colspan="1" rowspan="1">16 (72.7)</td>
                <td align="left" colspan="1" rowspan="1">21 (80.8)</td>
                <td align="left" colspan="1" rowspan="1">30 (51.7)</td>
                <td align="left" colspan="1" rowspan="1">37 (66.1)</td>
                <td align="left" colspan="1" rowspan="1">232 (55.6)</td>
                <td align="left" colspan="1" rowspan="1">337 (68.4)</td>
                <td align="left" colspan="1" rowspan="1">123 (52.6)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">BMI</td>
                <td align="left" colspan="1" rowspan="1">26.9 (5.1)</td>
                <td align="left" colspan="1" rowspan="1">27.4 (5.3)</td>
                <td align="left" colspan="1" rowspan="1">25.1 (4.5)</td>
                <td align="left" colspan="1" rowspan="1">25.9 (3.9)</td>
                <td align="left" colspan="1" rowspan="1">23.7 (6.3)</td>
                <td align="left" colspan="1" rowspan="1">26.2 (6.6)</td>
                <td align="left" colspan="1" rowspan="1">25.4 (4.2)</td>
                <td align="left" colspan="1" rowspan="1">27.3 (4.6)</td>
                <td align="left" colspan="1" rowspan="1">26.9 (3.5)</td>
                <td align="left" colspan="1" rowspan="1">25.0 (2.9)</td>
                <td align="left" colspan="1" rowspan="1">24.0 (3.2)</td>
                <td align="left" colspan="1" rowspan="1">24.5 (3.3)</td>
                <td align="left" colspan="1" rowspan="1">25.5 (4.7)</td>
                <td align="left" colspan="1" rowspan="1">26.3 (4.7)</td>
                <td align="left" colspan="1" rowspan="1">NA</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">Viral load<xref ref-type="table-fn" rid="nt103">c</xref></td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1">NS</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1"><italic>p</italic>&lt;0.05</td>
                <td align="left" colspan="1" rowspan="1">NA</td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt101">
              <label>a</label>
              <p>Unless otherwise specified, mean (SD) are presented.</p>
            </fn>
            <fn id="nt102">
              <label>b</label>
              <p><italic>p</italic>&lt;0.05 comparisons between responders (SVR) and NSVR based on the Ï<sup>2</sup> test.</p>
            </fn>
            <fn id="nt103">
              <label>c</label>
              <p>Comparisons between SVR and NSVR based on the Mann-Whitney test. Viral load was measured differently between cohorts, so the data are presented simply as a statistical comparison within cohorts.</p>
            </fn>
            <fn id="nt104">
              <label/>
              <p>NA, not available; NS, not significant.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <p>Samples from individuals with spontaneous clearance were collected from Westmead Hospital in Sydney (<italic>n</italic>â=â149), the Melbourne NETWORK study (<italic>n</italic>â=â31) <xref ref-type="bibr" rid="pmed.1001092-Dore1">[17]</xref>, the Australian ATACH study (<italic>n</italic>â=â18) <xref ref-type="bibr" rid="pmed.1001092-Aitken1">[18]</xref>, and Rheinische Friedrich-Wilhelms-Universitaet, Bonn, Germany (<italic>n</italic>â=â36). Spontaneous clearance was defined as HCV RNA negative and hepatitis C antibody positive without undergoing hepatitis C treatment.</p>
      </sec>
      <sec id="s2b">
        <title>Genotyping</title>
        <p>For <italic>HLA-C</italic>, samples were genotyped by multiplex PCR <xref ref-type="bibr" rid="pmed.1001092-Witt1">[19]</xref> to two-digit resolution. For samples from Turin and those participants with spontaneous virus clearance, <italic>HLA-C</italic> genotyping was by PCR and sequencing. All Australian samples were genotyped by multiplex PCR for <italic>KIR2DL2</italic> and <italic>KIR2DL3</italic> <xref ref-type="bibr" rid="pmed.1001092-Kulkarni1">[20]</xref>. <italic>KIR2DL2</italic> and <italic>KIR2DL3</italic> in the remainder and in those participants with spontaneous virus clearance and <italic>KIR2DS1</italic> and <italic>KIR2DS2</italic> in all samples were genotyped by PCR using the protocol of Ashouri et al. <xref ref-type="bibr" rid="pmed.1001092-Ashouri1">[21]</xref>. <italic>2DL1</italic> was not included owing to the fact that it is very common (&gt;90%), so we would have insufficient power to detect an association with its absence. The rs8099917 SNP was genotyped as previously reported <xref ref-type="bibr" rid="pmed.1001092-Suppiah1">[5]</xref>. The IL28B rs12979860 SNP was genotyped using a custom made Taqman genotyping kit. Further details are reported in <xref ref-type="supplementary-material" rid="pmed.1001092.s014">Text S1</xref>.</p>
      </sec>
      <sec id="s2c">
        <title>Statistical Analysis</title>
        <p>The Mann-Whitney and chi-squared tests were used to analyze baseline covariates. A chi-squared test was used to examine differences in allele, carriage, and genotype frequencies between SVR versus non-SVR (NSVR), those participants with spontaneous virus clearance (SC) versus CHC (i.e., NSVR plus SVR), and viral clearance (SC plus SVR) versus NSVR. The relationships between HLA-C, IL28B, and the KIR loci were investigated using logistic regression for predicting failure of SVR. Significance of all models was assessed by likelihood ratio (LR) tests. Analysis was carried out in R (v2.12).</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>IL28B Genotype and HCV Viral Clearance</title>
        <p>We had previously shown that the <italic>IL28B</italic> rs8099917 G allele predicts failure to clear HCV on PegIFN/R therapy <xref ref-type="bibr" rid="pmed.1001092-Suppiah1">[5]</xref>, in the CHC cohort now analysed here for <italic>HLA-C</italic> and <italic>KIR</italic> genotypes. Carriers of the G allele were under-represented in SC (odds ratio [OR] 0.26, <italic>p</italic>â=â1.71Ã10<sup>â14</sup>, 2.67â5.48) (<xref ref-type="table" rid="pmed-1001092-t002">Tables 2</xref> and <xref ref-type="supplementary-material" rid="pmed.1001092.s003">S1</xref>). The G allele appears to have a dominant effect, with both heterozygotes (OR 3.42, <italic>p</italic>â=â1.32Ã10<sup>â11</sup>, 2.36â4.96) and homozygotes (OR 3.25, <italic>p</italic>â=â1.78Ã10<sup>â2</sup>, 1.16â9.10) being similarly more likely to fail to clear virus spontaneously. SNP rs8099917 G carriers were 19.7% of SC, 27.5% of healthy controls (HapMap CEU [Utah residents with Northern or Western European ancestry] data), 37.9% of SVR, and 57.3% of NSVR (<xref ref-type="supplementary-material" rid="pmed.1001092.s003">Table S1</xref>). Overall, those who failed to clear the virus after therapy or without therapy (NSVR versus SVR and SC) were much less likely to have the rs8099917 TT genotype (OR 0.34, <italic>p</italic>â=â1.44Ã10<sup>â17</sup>) (<xref ref-type="supplementary-material" rid="pmed.1001092.s003">Table S1</xref>), with both heterozygotes (OR 2.59, <italic>p</italic>â=â5.91Ã10<sup>â14</sup>) and homozygotes (OR 2.12, <italic>p</italic>â=â7.54Ã10<sup>â3</sup>) for the G allele more likely to fail to clear virus.</p>
        <table-wrap id="pmed-1001092-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001092.t002</object-id><label>Table 2</label><caption>
            <title>Association of <italic>IL28B</italic> rs8099917 and <italic>HLA-C</italic> genotypes with viral clearance on therapy and spontaneous clearance.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pmed-1001092-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.t002" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1" width="84*"/>
              <col align="center" span="1" width="97*"/>
              <col align="center" span="1" width="84*"/>
              <col align="center" span="1" width="91*"/>
              <col align="center" span="1" width="91*"/>
              <col align="center" span="1" width="87*"/>
              <col align="center" span="1" width="93*"/>
              <col align="center" span="1" width="102*"/>
              <col align="center" span="1" width="91*"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Cohort</td>
                <td align="left" colspan="3" rowspan="1">IL28</td>
                <td align="left" colspan="3" rowspan="1">HLA-C</td>
                <td align="left" colspan="2" rowspan="1">IL28/HLA-C<xref ref-type="table-fn" rid="nt106">a</xref></td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">TT</td>
                <td align="left" colspan="1" rowspan="1">TG</td>
                <td align="left" colspan="1" rowspan="1">GG</td>
                <td align="left" colspan="1" rowspan="1">C1C1</td>
                <td align="left" colspan="1" rowspan="1">C1C2</td>
                <td align="left" colspan="1" rowspan="1">C2C2</td>
                <td align="left" colspan="1" rowspan="1">C1*TT</td>
                <td align="left" colspan="1" rowspan="1">C2C2 G*</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>SVR (</bold>
                  <bold>
                    <italic>n</italic>
                  </bold>
                  <bold>â=â398/390/389)</bold>
                  <xref ref-type="table-fn" rid="nt107">b</xref>
                </td>
                <td align="left" colspan="1" rowspan="1">247 (62.0)</td>
                <td align="left" colspan="1" rowspan="1">134 (33.7)</td>
                <td align="left" colspan="1" rowspan="1">17 (4.3)</td>
                <td align="left" colspan="1" rowspan="1">151 (38.7)</td>
                <td align="left" colspan="1" rowspan="1">185 (47.4)</td>
                <td align="left" colspan="1" rowspan="1">54 (13.8)</td>
                <td align="left" colspan="1" rowspan="1">200 (51.4)</td>
                <td align="left" colspan="1" rowspan="1">13 (3.3)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>NSVR (</bold>
                  <bold>
                    <italic>n</italic>
                  </bold>
                  <bold>â=â475/463/459)</bold>
                  <xref ref-type="table-fn" rid="nt107">b</xref>
                </td>
                <td align="left" colspan="1" rowspan="1">203 (42.7)</td>
                <td align="left" colspan="1" rowspan="1">239 (50.3)</td>
                <td align="left" colspan="1" rowspan="1">33 (6.9)</td>
                <td align="left" colspan="1" rowspan="1">180 (38.9)</td>
                <td align="left" colspan="1" rowspan="1">192 (41.5)</td>
                <td align="left" colspan="1" rowspan="1">91 (19.7)</td>
                <td align="left" colspan="1" rowspan="1">160 (34.9)</td>
                <td align="left" colspan="1" rowspan="1">53 (11.5)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>
                    <italic>p</italic>
                  </bold>
                  <bold>-Value</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>1.27Ã10<sup>â8</sup></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>7.35Ã10<sup>â7</sup></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">0.090</td>
                <td align="left" colspan="1" rowspan="1">1.0</td>
                <td align="left" colspan="1" rowspan="1">0.084</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.024</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>1.17Ã10<sup>â6</sup></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>8.83Ã10<sup>â6</sup></bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>OR, 95% CI</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.46, 0.35â0.60</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>2.0, 1.52â2.63</bold>
                </td>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">
                  <bold>1.52, 1.05â2.20</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.51, 0.38â0.67</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>3.78, 2.03â7.04</bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>Participants with spontaneous virus clearance (</bold>
                  <bold>
                    <italic>n</italic>
                  </bold>
                  <bold>â=â218/228/212)</bold>
                  <xref ref-type="table-fn" rid="nt106">a</xref>
                </td>
                <td align="left" colspan="1" rowspan="1">175 (80.3)</td>
                <td align="left" colspan="1" rowspan="1">39 (17.9)</td>
                <td align="left" colspan="1" rowspan="1">4 (1.8)</td>
                <td align="left" colspan="1" rowspan="1">95 (41.7)</td>
                <td align="left" colspan="1" rowspan="1">105 (46.1)</td>
                <td align="left" colspan="1" rowspan="1">28 (12.3)</td>
                <td align="left" colspan="1" rowspan="1">147 (69.3)</td>
                <td align="left" colspan="1" rowspan="1">2 (0.9)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>CHC (</bold>
                  <bold>
                    <italic>n</italic>
                  </bold>
                  <bold>â=â873/853/848)</bold>
                  <sup>c</sup>
                </td>
                <td align="left" colspan="1" rowspan="1">450 (51.5)</td>
                <td align="left" colspan="1" rowspan="1">373(42.7)</td>
                <td align="left" colspan="1" rowspan="1">50(5.7)</td>
                <td align="left" colspan="1" rowspan="1">331(38.8)</td>
                <td align="left" colspan="1" rowspan="1">377(44.2)</td>
                <td align="left" colspan="1" rowspan="1">145(17.0)</td>
                <td align="left" colspan="1" rowspan="1">360 (42.5)</td>
                <td align="left" colspan="1" rowspan="1">69 (6.5)</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>
                    <italic>p</italic>
                  </bold>
                  <bold>-Value</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>1.71Ã10<sup>â14</sup></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>1.32Ã10<sup>â11</sup></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.018</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">0.43</td>
                <td align="left" colspan="1" rowspan="1">0.62</td>
                <td align="left" colspan="1" rowspan="1">0.084</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>2.40Ã10<sup>â12</sup></bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>1.27Ã10<sup>â3</sup></bold>
                </td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>OR, 95% CI</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.26, 0.18â0.37</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>3.42, 2.36â4.96</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>3.25, 1.16â9.10</bold>
                </td>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1"/>
                <td align="left" colspan="1" rowspan="1">
                  <bold>0.33, 0.24â0.45</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>7.31, 1.78â30.06</bold>
                </td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt105">
              <label/>
              <p>Since the HLA-C genotype effect appears to be recessive, and IL28B genotype effect dominant, the genotypes of maximal difference are shown. C1*, C1 carriers; G*, G carriers. Comparisons with <italic>p</italic>&lt;0.05 are in bold.</p>
            </fn>
            <fn id="nt106">
              <label>a</label>
              <p><xref ref-type="supplementary-material" rid="pmed.1001092.s004">Table S2</xref> shows the data for all genotypes.</p>
            </fn>
            <fn id="nt107">
              <label>b</label>
              <p>Three different <italic>n</italic> represent the three sets of genotyping results being compared in this table, respectively.</p>
            </fn>
          </table-wrap-foot></table-wrap>
      </sec>
      <sec id="s3b">
        <title>HLA-C2C2 Predicts Poor Viral Clearance on Therapy</title>
        <p>The <italic>HLA-C1</italic> and <italic>C2</italic> variants are associated with a number of aspects of viral clearance. <italic>HLA-C2</italic> homozygotes were more likely to fail to clear virus on therapy than other genotypes (OR 1.52, <italic>p</italic>â=â0.025, 1.05â2.20) (<xref ref-type="fig" rid="pmed-1001092-g001">Figure 1</xref>; <xref ref-type="table" rid="pmed-1001092-t002">Table 2</xref>). The HLA-C effect on viral clearance seems to be a recessive trait, such that <italic>C1</italic> heterozygotes are no more susceptible to treatment failure than <italic>C1</italic> homozygotes. <italic>HLA-C2</italic> homozygosity was not different between those participants with spontaneous virus clearance and healthy European controls (data for healthy controls from <xref ref-type="bibr" rid="pmed.1001092-Dunne1">[22]</xref>,<xref ref-type="bibr" rid="pmed.1001092-Williams1">[23]</xref>) (see <xref ref-type="supplementary-material" rid="pmed.1001092.s004">Table S2</xref>). This important observation suggests that the difference in association of <italic>HLA-C</italic> genotype with viral clearance is due to response to therapy alone, not to the immune response in the absence of therapy. From two-digit genotyping of <italic>HLA-C</italic>, the <italic>C2</italic> variant conferring highest susceptibility to treatment failure is <italic>Cw*05</italic> (OR 1.43, <italic>p</italic>â=â0.047, 1.0â2.03) (<xref ref-type="supplementary-material" rid="pmed.1001092.s005">Table S3</xref>). The <italic>Cw*03</italic> variant of <italic>C1</italic> confers significant drug response (OR 0.61, <italic>p</italic>â=â1.64Ã10<sup>â3</sup>, 0.44â0.83).</p>
        <fig id="pmed-1001092-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pmed.1001092.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>Association of HLA-C genotype with viral clearance with and without therapy.</title>
            <p>OR is plotted against viral clearance for each comparison, plus or minus 95% confidence interval (CI). Vertical height of plotted points is in proportion to log (1/p) where â<italic>p</italic>â is the probability of observed association being by chance. ORs are shown for each comparison. G*, carrier of G allele.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.g001" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3c">
        <title>Effect of <italic>KIR</italic> Genes on Viral Clearance</title>
        <p>We tested if <italic>KIR2DL2</italic> or <italic>2DL3</italic> affected response to therapy, protection against development of CHC, or clearance of virus with or without PegIFN/R (<xref ref-type="supplementary-material" rid="pmed.1001092.s006">Table S4</xref>). As reported by others <xref ref-type="bibr" rid="pmed.1001092-Khakoo1">[13]</xref>,<xref ref-type="bibr" rid="pmed.1001092-Knapp1">[14]</xref>, we observed no effect of KIR genotype per se on viral clearance in any comparison. There was evidence of a similar trend between homozygosity of <italic>HLA-C1</italic> and <italic>KIR2DL3</italic> with SVR <xref ref-type="bibr" rid="pmed.1001092-Knapp1">[14]</xref>, and with spontaneous clearance <xref ref-type="bibr" rid="pmed.1001092-Khakoo1">[13]</xref>. Consistent with Knapp et al. <xref ref-type="bibr" rid="pmed.1001092-Knapp1">[14]</xref> and Khakoo et al. <xref ref-type="bibr" rid="pmed.1001092-Khakoo1">[13]</xref>, we found evidence that those infected with HCV and with the <italic>KIR2DL3/C2C2</italic> genotype, were more likely to fail to clear virus (OR 1.91, <italic>p</italic>â=â0.022, 1.09â3.36) (<xref ref-type="supplementary-material" rid="pmed.1001092.s007">Table S5</xref>) on therapy (NSVR versus SVR), and more common in those who failed to clear virus on therapy (NSVR) compared to those who did combined with those who cleared HCV without therapy (SVR+SC) (OR 2.08, <italic>p</italic>â=â3.00Ã10<sup>â3</sup>, 1.27â3.40).</p>
        <p>We next tested the combination of <italic>HLA-C</italic> alleles with <italic>KIR2DL3</italic> and <italic>2DL2</italic> genes (<xref ref-type="supplementary-material" rid="pmed.1001092.s008">Table S6</xref>). There was evidence of increased association with the complementary pairs, so that the combination of the <italic>C1</italic> variant <italic>Cw*03</italic> with its inhibiting genes was associated with increased treatment response: <italic>Cw*03</italic> alone OR is 0.61 (<italic>p</italic>â=â1.64Ã10<sup>â3</sup>, 0.44â0.83), with <italic>2DL2</italic> is 0.47 (<italic>p</italic>â=â1.19Ã10<sup>â3</sup>, 0.29â0.75), with <italic>2DL3</italic> is 0.49 (<italic>p</italic>â=â2.13Ã10<sup>â4</sup>, 0.33â0.72). Most of the <italic>C2</italic> association with treatment failure was due to allele <italic>Cw*05</italic> (OR 1.43, <italic>p</italic>â=â4.66Ã10<sup>â2</sup>, 1.0â2.03), with a larger effect in combination with the inactivating haplotype tagged by <italic>2DL3</italic> (OR 1.97, <italic>p</italic>â=â2.04Ã10<sup>â3</sup>, 1.28â3.06), but unaffected by <italic>2DL2</italic>.</p>
      </sec>
      <sec id="s3d">
        <title>Effect of Activating KIR Genes on Viral Clearance</title>
        <p>The KIR ligands on NK cells activated on ligation to HLA-C are KIR2DS2 for HLA-C1, and KIR2DS1 for HLA-C2. Increased activation could occur in <italic>HLA-C1</italic> carriers who are also carriers of <italic>KIR2DS2</italic>, and for <italic>HLA-C2</italic> carriers who are also carriers of <italic>KIR2DS1</italic>. However, we found no evidence that <italic>KIR2DS</italic> genotypes affected viral clearance either singly or in combination with <italic>HLA-C</italic> genotypes (<xref ref-type="supplementary-material" rid="pmed.1001092.s009">Tables S7</xref> and <xref ref-type="supplementary-material" rid="pmed.1001092.s010">S8</xref>), although from a logistic regression model, it seems that <italic>KIR2DS1</italic> could mitigate the effect of <italic>HLA-C2C2</italic> (see below).</p>
      </sec>
      <sec id="s3e">
        <title>Combined Effect of HLA-C and IL28B Genotypes</title>
        <p>Prediction of failure to clear HCV in response to treatment with either <italic>IL28B</italic> or <italic>HLA-C</italic> genotypes alone is of limited value clinically due to the relatively low positive predictive value (PPV) for treatment failure <xref ref-type="bibr" rid="pmed.1001092-Ahlenstiel2">[24]</xref>. We therefore tested if both genotypes together provided additional power to predict response. Indeed, the combination significantly improves prediction of failure to clear virus on therapy (OR 3.78, <italic>p</italic>â=â8.83Ã10<sup>â6</sup>, 2.03â7.04), failure to clear virus spontaneously (OR 7.31, <italic>p</italic>â=â1.27Ã10<sup>â3</sup>, 1.78â30.06), and failure to clear virus with and without therapy (OR 5.10, <italic>p</italic>â=â2.53Ã10<sup>â9</sup>, 2.84â9.17) (<xref ref-type="table" rid="pmed-1001092-t002">Tables 2</xref> and <xref ref-type="supplementary-material" rid="pmed.1001092.s011">S9a</xref>). The largest difference was between those participants with spontaneous virus clearance and those who failed to clear virus on therapy (<xref ref-type="fig" rid="pmed-1001092-g002">Figure 2</xref>). As shown in <xref ref-type="table" rid="pmed-1001092-t003">Table 3</xref>, prediction of treatment failure improved from 66% for <italic>IL28B</italic> G to 80% with <italic>IL28B</italic> G*/<italic>C2C2</italic>.</p>
        <fig id="pmed-1001092-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pmed.1001092.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Proportion of each cohort with the HLA-C2C2 and IL28B G* genotype, which predicts treatment failure.</title>
            <p>HC, healthy controls; G*, carrier of G allele. Lines connect the significant 2Ã2 chi-squared comparisons with associated <italic>p</italic>-values and ORs. HC numbers obtained from Williams et al. <xref ref-type="bibr" rid="pmed.1001092-Williams1">[23]</xref> and Dunne et al. <xref ref-type="bibr" rid="pmed.1001092-Dunne1">[22]</xref>.</p>
          </caption>
          <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.g002" xlink:type="simple"/>
        </fig>
        <table-wrap id="pmed-1001092-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001092.t003</object-id><label>Table 3</label><caption>
            <title>Prediction of failure to clear virus on therapy with PegIFN/R.</title>
          </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pmed-1001092-t003-3" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.t003" xlink:type="simple"/><table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" colspan="1" rowspan="1">Genotype</td>
                <td align="left" colspan="1" rowspan="1">Sensitivity</td>
                <td align="left" colspan="1" rowspan="1">Specificity</td>
                <td align="left" colspan="1" rowspan="1">Positive Predictive Value</td>
                <td align="left" colspan="1" rowspan="1">Negative Predictive Value</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>IL28GG</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">7</td>
                <td align="left" colspan="1" rowspan="1">96</td>
                <td align="left" colspan="1" rowspan="1">66</td>
                <td align="left" colspan="1" rowspan="1">46</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>IL28G*</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">57</td>
                <td align="left" colspan="1" rowspan="1">62</td>
                <td align="left" colspan="1" rowspan="1">64</td>
                <td align="left" colspan="1" rowspan="1">55</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>HLA-C2C2</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">20</td>
                <td align="left" colspan="1" rowspan="1">86</td>
                <td align="left" colspan="1" rowspan="1">63</td>
                <td align="left" colspan="1" rowspan="1">47</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>HLA C2*</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">61</td>
                <td align="left" colspan="1" rowspan="1">39</td>
                <td align="left" colspan="1" rowspan="1">54</td>
                <td align="left" colspan="1" rowspan="1">46</td>
              </tr>
              <tr>
                <td align="left" colspan="1" rowspan="1">
                  <bold>IL28G*/HLA-C2C2</bold>
                </td>
                <td align="left" colspan="1" rowspan="1">12</td>
                <td align="left" colspan="1" rowspan="1">97</td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>80</bold>
                  <xref ref-type="table-fn" rid="nt108"/>
                </td>
                <td align="left" colspan="1" rowspan="1">
                  <bold>48</bold>
                  <xref ref-type="table-fn" rid="nt108"/>
                </td>
              </tr>
            </tbody>
          </table></alternatives><table-wrap-foot>
            <fn id="nt108">
              <label/>
              <p>Positive predictive value and negative predictive value for best genotype are in bold.</p>
            </fn>
          </table-wrap-foot></table-wrap>
        <p>A similar predictive value for treatment response has been reported for <italic>IL28B</italic> SNP rs12979860<sup>[4] </sup>We found that the PPV derived from combining this SNP and <italic>HLA-C2C2</italic> was actually lower in this cohort than for the rs8099917 combination (OR 2.52, <italic>p</italic>â=â5.18Ã10<sup>â5</sup>, 1.59â3.98) (<xref ref-type="supplementary-material" rid="pmed.1001092.s011">Table S9b</xref>). Adding the clinical features of age, gender, body mass index, or viral load improved predictive value (<xref ref-type="supplementary-material" rid="pmed.1001092.s001">Figure S1</xref>, responder operator curves).</p>
      </sec>
      <sec id="s3f">
        <title>Interactions between IL28B, HLA-C, and KIR</title>
        <p>Using a logistic regression model, the increased OR of 3.78 for the combination rs8099917, G*/C2C2 is partially due to genetic interaction (LR, <italic>p</italic>&lt;0.05) (<xref ref-type="supplementary-material" rid="pmed.1001092.s012">Table S10</xref>), and not just an additive effect. Examining the relationship between <italic>KIR</italic> genotype and either <italic>HLA-C2C2</italic> or <italic>IL28B</italic> rs8099917 G*, we found no evidence for any two-way interactions for predicting failure of SVR. For the three-way interaction model between HLA-C, IL28, and not 2DS1, although the coefficient for the three-way interaction is significant, the LR test concludes that the model does not produce a significantly better fit (LR, <italic>p</italic>â=â0.28). Although the HLA-C main effect is not significant via a standard <italic>t</italic>-test in the interaction model, it is associated with response (<xref ref-type="table" rid="pmed-1001092-t002">Table 2</xref>). Adding HLA-C to a model including rs8099917 leads to significant improvement of the fit (LR, <italic>p</italic>â=â0.006), implying that HLA-C has an independent affect on response and should be included in the model. Adding the interaction term again improves the model fit (LR, <italic>p</italic>â=â0.03).</p>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>The IL28B genotype is already used to predict treatment response to PegIFN/R in clinical practice, even though its association with therapeutic response was only first identified in late 2009. We tested the <italic>IL28B</italic>, <italic>HLA-C</italic>, and <italic>KIR</italic> gene variant associations with treatment-induced and spontaneous clearance of HCV and confirmed that <italic>IL28B</italic> rs8099917 predicts clearance in both situations. The <italic>HLA-C2C2</italic> genotype predicted failure to clear HCV on treatment, but no association with failure to clear HCV without treatment was detected. The prediction of treatment-induced clearance was additive and interactive between <italic>IL28B</italic> and <italic>HLA-C</italic>; and there was evidence of additive and interactive effects between <italic>KIR2DL3</italic>, <italic>KIR2DS1</italic>, and <italic>HLA-C2C2</italic>. These data and previous reports point to <italic>HLA-C</italic> as being the second gene predicting PegIFN/R treatment response in HCV. This genetic evidence supports an underlying physiological mechanism for HCV viral control involving an interaction between <italic>IL28B</italic>, <italic>HLA-C</italic>, and <italic>KIR</italic>s.</p>
      <p>Khakoo et al. <xref ref-type="bibr" rid="pmed.1001092-Khakoo1">[13]</xref> and Dring et al. <xref ref-type="bibr" rid="pmed.1001092-Dring1">[25]</xref> compared <italic>HLA-C</italic> and <italic>KIR</italic> genotypes between those participants with spontaneous virus clearance and CHC, and Knapp et al. <xref ref-type="bibr" rid="pmed.1001092-Knapp1">[14]</xref> in these and in treatment response. As in our study, Khakoo et al. reported <italic>HLA-C2</italic> homozygotes were more common in CHC than SC (OR 1.49, <italic>p</italic>â=â0.02), and <italic>KIR2DL3-C2</italic> homozygotes slightly more so (OR 1.87, <italic>p</italic>â=â0.01); and Dring et al. reported KIR2DS3-C2 carriers were more common in CHC than SC (OR 2.26, <italic>p</italic>â=â0.002). Knapp et al. detected a trend towards C2 excess in those who failed to clear virus spontaneously compared to CHC (OR 1.69, <italic>p</italic>â=â0.10), a trend of C2 excess in NSVR versus SVR (OR 1.38, <italic>p</italic>â=â0.27) <xref ref-type="bibr" rid="pmed.1001092-Khakoo1">[13]</xref>, but no difference between SVR and SC. In both the Knapp study and ours, the <italic>KIR2DL3-C1</italic> homozygotes were more common in SVR, and most of this association was due to the <italic>C1-Cw*03</italic> variant. <italic>KIR2DL3</italic> tags haplotype A, which contains fewer activating <italic>KIR</italic> genes. This association is consistent with insufficient activation of NK cells in the context of HLA-C2C2 inhibition as the basis for increased risk of treatment failure.</p>
      <p>Dring et al. <xref ref-type="bibr" rid="pmed.1001092-Dring1">[25]</xref> identified a dramatic synergy between KIR2DS3 (not examined here, encoded on haplotype B) and the IL28B SNP rs12979860 in predicting spontaneous clearance in a unusually homogenous cohort of Irish females infected with genotype 1 HCV by transfusion. They also showed that IFNÎ» inhibited IFNÎ³ production by NK cells. They did not examine SNP rs8099917 or SVR and NSVR. Their data further support NK function in HCV clearance as being influenced by IFNÎ».</p>
      <p>Because of the very high linkage disequilibrium in the MHC class I region around <italic>HLA-C</italic>, the association we and others have observed may be due to <italic>HLA-C</italic> variants tagging other class I genes. However, the KIR interactions, which are HLA-C specific, support the signal being due to <italic>HLA-C</italic> itself, as does the strong body of evidence pointing to the importance of NK cells in killing virally infected cells in response to interferon and tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) (reviewed in <xref ref-type="bibr" rid="pmed.1001092-Ahlenstiel3">[26]</xref>â<xref ref-type="bibr" rid="pmed.1001092-Stegmann1">[28]</xref>). In addition, activated NK cells recognize and lyse HCV replicon-containing hepatoma cells in vitro <xref ref-type="bibr" rid="pmed.1001092-Lee1">[27]</xref> and should therefore be able to kill virus-infected hepatocytes in vivo. Cells that lack or have downregulated MHC class I molecules, such as virally infected cells or tumour cells, are susceptible to NK cell-mediated killing. In this context it has been reported that IFNÎ»3 (the protein encoded by <italic>IL28B</italic>) augments the antitumor activity of NK cells <xref ref-type="bibr" rid="pmed.1001092-Numasaki1">[11]</xref>,<xref ref-type="bibr" rid="pmed.1001092-Lee1">[27]</xref>.</p>
      <p>The association of HLA-C with viral clearance on treatment but not spontaneous clearance suggests that, on therapy, NK killing of hepatocytes is augmented in <italic>HLA-C1</italic> carriers compared to C2 homozygotes. There are numerous potential mechanisms by which <italic>HLA-C</italic> genotypes could affect NK cell activity in the context of IFNÎ± treatment. IFNÎ± could affect NK killing of HCV-infected hepatocytes. IFNÎ± is known to increase NK sensitivity to activation <xref ref-type="bibr" rid="pmed.1001092-Lee1">[27]</xref>, but also to directly activate NK cells in patients with HCV infection and induced a strongly cytotoxic phenotype <xref ref-type="bibr" rid="pmed.1001092-Lee1">[27]</xref>. This NK cell activation and killing of hepatocytes is affected by the <italic>HLA-C</italic> genotype: the C1 allele allowing activation more rapidly and aggressively <xref ref-type="bibr" rid="pmed.1001092-Ahlenstiel1">[16]</xref>. <italic>HLA-C</italic> may be even more upregulated in response to IFNÎ± <xref ref-type="bibr" rid="pmed.1001092-Marcello1">[29]</xref>, making it more difficult for C2 homozygotes to activate NK cells.</p>
      <p>The association of <italic>IL28B</italic> genotype with SC and therapeutic response indicates that IFNÎ»3 affects viral clearance. IFNÎ»3 is likely to enhance antiviral mechanisms through upregulation of interferon-stimulated genes (ISGs) in acute disease <xref ref-type="bibr" rid="pmed.1001092-Ahlenstiel2">[24]</xref>, but its effect may be more complicated in chronic infection, in which upregulation of ISGs in liver is associated with reduced treatment response <xref ref-type="bibr" rid="pmed.1001092-Honda1">[30]</xref>. One approach to identifying the molecular pathways through which a genetic variant affects disease outcome is to identify other genes that affect pathogenesis, and especially those with which it may interact. The additive association of <italic>HLA-C</italic> and <italic>IL28B</italic> genotypes with treatment-induced clearance, but not spontaneous clearance, suggests <italic>IL28B</italic> may be enhancing NK killing on PegIFN/R therapy. <italic>HLA-C</italic> is one of the most upregulated genes following treatment of a cell line with IFNÎ»3 <xref ref-type="bibr" rid="pmed.1001092-Marcello1">[29]</xref>. The degree of this upregulation may depend on <italic>HLA-C</italic> genotype.</p>
      <p>The larger predictive value for HLA-C2C2 and IL28B rs8099917 G* than SNP rs12979860 T* may indicate different haplotype effects. There are five common <italic>IL28B</italic> haplotypes in Caucasians <xref ref-type="bibr" rid="pmed.1001092-Suppiah1">[5]</xref>. The rs8099917 minor allele tags the haplotype with the highest association with therapeutic response, whilst rs12979860 minor alleles are on this haplotype and others (<xref ref-type="supplementary-material" rid="pmed.1001092.s013">Table S11</xref>). Ge et al. <xref ref-type="bibr" rid="pmed.1001092-Ge1">[4]</xref> reported that there was evidence of independent effects of the two haplotypes. Therefore the additive effect of <italic>HLA-C</italic> with <italic>IL28B</italic> may be only with the rs8099917-tagged haplotype. It is likely that these two SNPs, which were on genotyping chips, will be supplanted by others when a more comprehensive analysis of the genetic variation of IL28B is available.</p>
      <p>The overall differences in frequency of <italic>HLA-C2C2/IL28B</italic> G* in healthy controls, those participants with spontaneous virus clearance, SVR, and NSVR groups suggests a role in pathogenesis for this gene combination. It is also striking that <italic>HLA-C2C2</italic> frequency is highly variable between ethnic groups, roughly in proportion to their treatment responsiveness (<xref ref-type="supplementary-material" rid="pmed.1001092.s002">Figure S2</xref>). Much of the variation between African Americans and European Americans has been explained by the <italic>IL28B</italic> rs12979860 SNP <xref ref-type="bibr" rid="pmed.1001092-Ge1">[4]</xref>, but it seems likely that the higher proportion of the <italic>HLA-C2C2</italic> genotype in African Americans may also contribute to their reduced viral clearance.</p>
      <p>With regard to patient management, avoiding treatment in those less likely to respond to PegIFN/R is important given the toxicity of this treatment and the likelihood that one or multiple direct acting antiviral agents will soon be available <xref ref-type="bibr" rid="pmed.1001092-Kwo1">[31]</xref>,<xref ref-type="bibr" rid="pmed.1001092-McHutchison1">[32]</xref>. In this context, <italic>IL28B</italic> genotype alone allows prediction of failure of PegIFN/R in only 66% of patients (<xref ref-type="table" rid="pmed-1001092-t003">Table 3</xref>). We have shown that with <italic>HLA-C</italic> genotyping this can be improved to a clinically more meaningful 80%. Genotyping of <italic>IL28B</italic> and <italic>HLA-C</italic> to C1/C2 is rapid and inexpensive. Further genetic associations, including those affecting HLA-C/IFNÎ» interactions, viral sequence variability <xref ref-type="bibr" rid="pmed.1001092-Akuta1">[33]</xref>, and host/virus interactions such as IP-10 levels <xref ref-type="bibr" rid="pmed.1001092-Askarieh1">[34]</xref> might further enhance prediction of treatment outcomes.</p>
      <p>In addition to supporting the importance of <italic>HLA-C</italic>, <italic>KIR</italic>, and <italic>IL28B</italic> in HCV clearance and drug response, and emphasizing the role of NK cells in the outcomes of HCV infection, this study highlights the value of investigating variants other than SNPs to identify genetic variants causing disease and drug response. Notably, independent replication of these data in Europeans, and testing them for the first time in African-Americans and other ethnic groups is required.</p>
    </sec>
    <sec id="s6">
      <title>Supporting Information</title>
      <supplementary-material id="pmed.1001092.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s001" xlink:type="simple">
        <label>Figure S1</label>
        <caption>
          <p>Responder operator curves for prediction of failure to clear virus on therapy based on clinical and genotyping data.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s002" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s002" xlink:type="simple">
        <label>Figure S2</label>
        <caption>
          <p>Proportion of each ethnic group with the genotype that predicts treatment failure: <italic>HLA-C2C2</italic> homozygotes and <italic>IL28B</italic> G carriers.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s003" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s003" xlink:type="simple">
        <label>Table S1</label>
        <caption>
          <p>Association of <italic>IL28B</italic> rs8099917 genotypes with viral clearance with and without therapy.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s004" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s004" xlink:type="simple">
        <label>Table S2</label>
        <caption>
          <p>Comparison of <italic>HLA-C</italic> group 1 and 2 allele and genotype distribution from previous studies.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s005" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s005" xlink:type="simple">
        <label>Table S3</label>
        <caption>
          <p><italic>HLA-C</italic> (two-digit genotyping) in SVR and NSVR.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s006" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s006" xlink:type="simple">
        <label>Table S4</label>
        <caption>
          <p>Association of HLA-C inhibitory receptor genes <italic>KIR2DL2</italic> and <italic>KIR2DL3</italic> on viral clearance with and without therapy.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s007" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s007" xlink:type="simple">
        <label>Table S5</label>
        <caption>
          <p>Association of HLA-C inhibitory receptor genes <italic>KIR2DL2</italic> and <italic>KIR2DL3</italic> on viral clearance with and without therapy in combination with <italic>HLA-C</italic> genotypes.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s008" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s008" xlink:type="simple">
        <label>Table S6</label>
        <caption>
          <p>Association of HLA-C inhibitory receptor genes <italic>KIR2DL2</italic> and <italic>KIR2DL3</italic> on viral clearance in combination with <italic>HLA-C</italic> genotypes based on two-digit genotyping.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s009" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s009" xlink:type="simple">
        <label>Table S7</label>
        <caption>
          <p>Association of HLA-C activating receptor genes <italic>KIR2DS1</italic> and <italic>KIR2DS2</italic> on viral clearance with and without therapy.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s010" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s010" xlink:type="simple">
        <label>Table S8</label>
        <caption>
          <p>Association of HLA-C activating receptor genes <italic>KIR2DS1</italic> and <italic>KIR2DS2</italic> on viral clearance with and without therapy in combination with <italic>HLA-C</italic> genotypes.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s011" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s011" xlink:type="simple">
        <label>Table S9</label>
        <caption>
          <p>(<bold>a</bold>) Association of combinations of <italic>IL28B</italic> SNP rs8099917 and <italic>HLA-C</italic> genotypes on viral clearance with and without therapy. (<bold>b</bold>) Association of combinations of <italic>IL28B</italic> SNP rs12979860 and <italic>HLA-C</italic> genotypes on viral clearance with therapy.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s012" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s012" xlink:type="simple">
        <label>Table S10</label>
        <caption>
          <p>Odds ratios and corresponding <italic>p</italic>-values for predicting failure of SVR using logistic regression models.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s013" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s013" xlink:type="simple">
        <label>Table S11</label>
        <caption>
          <p>The distribution of the six common IL28B haplotypes bound by SNPs rs12980275 and rs8099917.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pmed.1001092.s014" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001092.s014" xlink:type="simple">
        <label>Text S1</label>
        <caption>
          <p>Supplementary methods.</p>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We would like to thank all patients for their valuable participation in this study. The IHCGC team includes Monika Michalk from University of Bonn; Barbara Malik from UniversitÃ¤tsmedizin Berlin; Patrick McClure and Sherie Smith from the University of Nottingham; Elizabeth Snape and Vincenzo Fragomeli from Nepean Hospital; Richard Norris and Dianne How-Chow from St Vincent's Hospital; Julie R. Jonsson and Helen Barrie from Princess Alexandra Hospital; Sacha Stelzer-Braid and Shona Fletcher from Prince of Wales Hospital; Tanya Applegate and Jason Grebely from the National Centre in HIV Epidemiology and Clinical Research and Mandvi Bharadwaj from the Burnet Institute. We would also like to thank Reynold Leung for technical assistance.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pmed.1001092-Micallef1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Micallef</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kaldor</surname><given-names>JM</given-names></name><name name-style="western"><surname>Dore</surname><given-names>GJ</given-names></name></person-group>             <year>2006</year>             <article-title>Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.</article-title>             <source>J Viral Hepat</source>             <volume>13</volume>             <fpage>34</fpage>             <lpage>41</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Hoofnagle1">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Hoofnagle</surname><given-names>JH</given-names></name></person-group>             <year>2002</year>             <article-title>Course and outcome of hepatitis C.</article-title>             <source>Hepatology</source>             <volume>36</volume>             <fpage>S21</fpage>             <lpage>S29</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Feld1">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Feld</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Hoofnagle</surname><given-names>JH</given-names></name></person-group>             <year>2005</year>             <article-title>Mechanism of action of interferon and ribavirin in treatment of hepatitis C.</article-title>             <source>Nature</source>             <volume>436</volume>             <fpage>967</fpage>             <lpage>972</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Ge1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>D</given-names></name><name name-style="western"><surname>Fellay</surname><given-names>J</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Simon</surname><given-names>JS</given-names></name><name name-style="western"><surname>Shianna</surname><given-names>KV</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.</article-title>             <source>Nature</source>             <volume>461</volume>             <fpage>399</fpage>             <lpage>401</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Suppiah1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Suppiah</surname><given-names>V</given-names></name><name name-style="western"><surname>Moldovan</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahlenstiel</surname><given-names>G</given-names></name><name name-style="western"><surname>Berg</surname><given-names>T</given-names></name><name name-style="western"><surname>Weltman</surname><given-names>M</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.</article-title>             <source>Nat Genet</source>             <volume>41</volume>             <fpage>1100</fpage>             <lpage>1104</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Tanaka1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>N</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>M</given-names></name><name name-style="western"><surname>Kurosaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>K</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.</article-title>             <source>Nat Genet</source>             <volume>41</volume>             <fpage>1105</fpage>             <lpage>1109</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Thomas1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>DL</given-names></name><name name-style="western"><surname>Thio</surname><given-names>CL</given-names></name><name name-style="western"><surname>Martin</surname><given-names>MP</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ge</surname><given-names>D</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.</article-title>             <source>Nature</source>             <volume>461</volume>             <fpage>798</fpage>             <lpage>801</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Afdhal1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Afdhal</surname><given-names>NH</given-names></name><name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name><name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></name><name name-style="western"><surname>Mangia</surname><given-names>A</given-names></name><name name-style="western"><surname>Pawlotsky</surname><given-names>JM</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Hepatitis C pharmacogenetics: state of the art in 2010.</article-title>             <source>Hepatology</source>             <volume>53</volume>             <fpage>336</fpage>             <lpage>345</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Colonna1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Colonna</surname><given-names>M</given-names></name><name name-style="western"><surname>Borsellino</surname><given-names>G</given-names></name><name name-style="western"><surname>Falco</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>GB</given-names></name><name name-style="western"><surname>Strominger</surname><given-names>JL</given-names></name></person-group>             <year>1993</year>             <article-title>HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>90</volume>             <fpage>12000</fpage>             <lpage>12004</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Wagtmann1">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Wagtmann</surname><given-names>N</given-names></name><name name-style="western"><surname>Rajagopalan</surname><given-names>S</given-names></name><name name-style="western"><surname>Winter</surname><given-names>CC</given-names></name><name name-style="western"><surname>Peruzzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Long</surname><given-names>EO</given-names></name></person-group>             <year>1995</year>             <article-title>Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer.</article-title>             <source>Immunity</source>             <volume>3</volume>             <fpage>801</fpage>             <lpage>809</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Numasaki1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Numasaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Tagawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>F</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>A</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>IL-28 elicits antitumor responses against murine fibrosarcoma.</article-title>             <source>J Immunol</source>             <volume>178</volume>             <fpage>5086</fpage>             <lpage>5098</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Sato1">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>A</given-names></name><name name-style="western"><surname>Ohtsuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Hata</surname><given-names>M</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>E</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>T</given-names></name></person-group>             <year>2006</year>             <article-title>Antitumor activity of IFN-lambda in murine tumor models.</article-title>             <source>J Immunol</source>             <volume>176</volume>             <fpage>7686</fpage>             <lpage>7694</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Khakoo1">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Khakoo</surname><given-names>SI</given-names></name><name name-style="western"><surname>Thio</surname><given-names>CL</given-names></name><name name-style="western"><surname>Martin</surname><given-names>MP</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>CR</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><etal/></person-group>             <year>2004</year>             <article-title>HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection.</article-title>             <source>Science</source>             <volume>305</volume>             <fpage>872</fpage>             <lpage>874</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Knapp1">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Knapp</surname><given-names>S</given-names></name><name name-style="western"><surname>Warshow</surname><given-names>U</given-names></name><name name-style="western"><surname>Hegazy</surname><given-names>D</given-names></name><name name-style="western"><surname>Brackenbury</surname><given-names>L</given-names></name><name name-style="western"><surname>Guha</surname><given-names>IN</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.</article-title>             <source>Hepatology</source>             <volume>51</volume>             <fpage>1168</fpage>             <lpage>1175</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-VidalCastineira1">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Vidal-Castineira</surname><given-names>JR</given-names></name><name name-style="western"><surname>Lopez-Vazquez</surname><given-names>A</given-names></name><name name-style="western"><surname>Diaz-Pena</surname><given-names>R</given-names></name><name name-style="western"><surname>Alonso-Arias</surname><given-names>R</given-names></name><name name-style="western"><surname>Martinez-Borra</surname><given-names>J</given-names></name><etal/></person-group>             <year>2009</year>             <article-title>Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.</article-title>             <source>J Virol</source>             <volume>84</volume>             <fpage>475</fpage>             <lpage>481</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Ahlenstiel1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ahlenstiel</surname><given-names>G</given-names></name><name name-style="western"><surname>Martin</surname><given-names>MP</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Carrington</surname><given-names>M</given-names></name><name name-style="western"><surname>Rehermann</surname><given-names>B</given-names></name></person-group>             <year>2008</year>             <article-title>Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses.</article-title>             <source>J Clin Invest</source>             <volume>118</volume>             <fpage>1017</fpage>             <lpage>1026</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Dore1">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dore</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Hellard</surname><given-names>M</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>GV</given-names></name><name name-style="western"><surname>Grebely</surname><given-names>J</given-names></name><name name-style="western"><surname>Haber</surname><given-names>PS</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Effective treatment of injecting drug users with recently acquired hepatitis C virus infection.</article-title>             <source>Gastroenterology</source>             <volume>138</volume>             <fpage>123</fpage>             <lpage>135 e121â122</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Aitken1">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Aitken</surname><given-names>CK</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>SL</given-names></name><name name-style="western"><surname>Spelman</surname><given-names>T</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>DS</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.</article-title>             <source>Hepatology</source>             <volume>48</volume>             <fpage>1746</fpage>             <lpage>1752</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Witt1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Witt</surname><given-names>CS</given-names></name><name name-style="western"><surname>Price</surname><given-names>P</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>G</given-names></name><name name-style="western"><surname>Cheong</surname><given-names>K</given-names></name><name name-style="western"><surname>Kanga</surname><given-names>U</given-names></name><etal/></person-group>             <year>2002</year>             <article-title>Common HLA-B8-DR3 haplotype in Northern India is different from that found in Europe.</article-title>             <source>Tissue Antigens</source>             <volume>60</volume>             <fpage>474</fpage>             <lpage>480</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Kulkarni1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>S</given-names></name><name name-style="western"><surname>Martin</surname><given-names>MP</given-names></name><name name-style="western"><surname>Carrington</surname><given-names>M</given-names></name></person-group>             <year>2010</year>             <article-title>KIR genotyping by multiplex PCR-SSP.</article-title>             <source>Methods Mol Biol</source>             <volume>612</volume>             <fpage>365</fpage>             <lpage>375</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Ashouri1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ashouri</surname><given-names>E</given-names></name><name name-style="western"><surname>Ghaderi</surname><given-names>A</given-names></name><name name-style="western"><surname>Reed</surname><given-names>EF</given-names></name><name name-style="western"><surname>Rajalingam</surname><given-names>R</given-names></name></person-group>             <year>2009</year>             <article-title>A novel duplex SSP-PCR typing method for KIR gene profiling.</article-title>             <source>Tissue Antigens</source>             <volume>74</volume>             <fpage>62</fpage>             <lpage>67</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Dunne1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dunne</surname><given-names>C</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>J</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>R</given-names></name><name name-style="western"><surname>Rooney</surname><given-names>G</given-names></name><name name-style="western"><surname>Lawlor</surname><given-names>E</given-names></name></person-group>             <year>2008</year>             <article-title>HLA-A, B, Cw, DRB1, DQB1 and DPB1 alleles and haplotypes in the genetically homogenous Irish population.</article-title>             <source>Int J Immunogenet</source>             <volume>35</volume>             <fpage>295</fpage>             <lpage>302</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Williams1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>F</given-names></name><name name-style="western"><surname>Meenagh</surname><given-names>A</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>C</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>D</given-names></name></person-group>             <year>2002</year>             <article-title>Molecular diversity of the HLA-C gene identified in a caucasian population.</article-title>             <source>Hum Immunol</source>             <volume>63</volume>             <fpage>602</fpage>             <lpage>613</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Ahlenstiel2">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ahlenstiel</surname><given-names>G</given-names></name><name name-style="western"><surname>Booth</surname><given-names>DR</given-names></name><name name-style="western"><surname>George</surname><given-names>J</given-names></name></person-group>             <year>2010</year>             <article-title>IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.</article-title>             <source>J Gastroenterol</source>             <volume>45</volume>             <fpage>903</fpage>             <lpage>910</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Dring1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Dring</surname><given-names>MM</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>MH</given-names></name><name name-style="western"><surname>McSharry</surname><given-names>BP</given-names></name><name name-style="western"><surname>Guinan</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>R</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>108</volume>             <fpage>5736</fpage>             <lpage>5741</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Ahlenstiel3">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Ahlenstiel</surname><given-names>G</given-names></name><name name-style="western"><surname>Titerence</surname><given-names>RH</given-names></name><name name-style="western"><surname>Koh</surname><given-names>C</given-names></name><name name-style="western"><surname>Edlich</surname><given-names>B</given-names></name><name name-style="western"><surname>Feld</surname><given-names>JJ</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.</article-title>             <source>Gastroenterology</source>             <volume>138</volume>             <fpage>325</fpage>             <lpage>335 e321â322</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Lee1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Miyagi</surname><given-names>T</given-names></name><name name-style="western"><surname>Biron</surname><given-names>CA</given-names></name></person-group>             <year>2007</year>             <article-title>Keeping NK cells in highly regulated antiviral warfare.</article-title>             <source>Trends Immunol</source>             <volume>28</volume>             <fpage>252</fpage>             <lpage>259</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Stegmann1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Stegmann</surname><given-names>KA</given-names></name><name name-style="western"><surname>Bjorkstrom</surname><given-names>NK</given-names></name><name name-style="western"><surname>Veber</surname><given-names>H</given-names></name><name name-style="western"><surname>Ciesek</surname><given-names>S</given-names></name><name name-style="western"><surname>Riese</surname><given-names>P</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.</article-title>             <source>Gastroenterology</source>             <volume>138</volume>             <fpage>1885</fpage>             <lpage>1897</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Marcello1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Marcello</surname><given-names>T</given-names></name><name name-style="western"><surname>Grakoui</surname><given-names>A</given-names></name><name name-style="western"><surname>Barba-Spaeth</surname><given-names>G</given-names></name><name name-style="western"><surname>Machlin</surname><given-names>ES</given-names></name><name name-style="western"><surname>Kotenko</surname><given-names>SV</given-names></name><etal/></person-group>             <year>2006</year>             <article-title>Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.</article-title>             <source>Gastroenterology</source>             <volume>131</volume>             <fpage>1887</fpage>             <lpage>1898</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Honda1">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Honda</surname><given-names>M</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>A</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mizukoshi</surname><given-names>E</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.</article-title>             <source>Gastroenterology</source>             <volume>139</volume>             <fpage>499</fpage>             <lpage>509</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Kwo1">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Kwo</surname><given-names>PY</given-names></name><name name-style="western"><surname>Lawitz</surname><given-names>EJ</given-names></name><name name-style="western"><surname>McCone</surname><given-names>J</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>ER</given-names></name><name name-style="western"><surname>Vierling</surname><given-names>JM</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.</article-title>             <source>Lancet</source>             <volume>376</volume>             <fpage>705</fpage>             <lpage>716</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-McHutchison1">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name><name name-style="western"><surname>Manns</surname><given-names>MP</given-names></name><name name-style="western"><surname>Muir</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Terrault</surname><given-names>NA</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>IM</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Telaprevir for previously treated chronic HCV infection.</article-title>             <source>N Engl J Med</source>             <volume>362</volume>             <fpage>1292</fpage>             <lpage>1303</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Akuta1">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Akuta</surname><given-names>N</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>F</given-names></name><name name-style="western"><surname>Hirakawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Kawamura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yatsuji</surname><given-names>H</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.</article-title>             <source>Hepatology</source>             <volume>52</volume>             <fpage>421</fpage>             <lpage>429</lpage>          </element-citation>
      </ref>
      <ref id="pmed.1001092-Askarieh1">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author"><name name-style="western"><surname>Askarieh</surname><given-names>G</given-names></name><name name-style="western"><surname>Alsio</surname><given-names>A</given-names></name><name name-style="western"><surname>Pugnale</surname><given-names>P</given-names></name><name name-style="western"><surname>Negro</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>C</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.</article-title>             <source>Hepatology</source>             <volume>51</volume>             <fpage>1523</fpage>             <lpage>1530</lpage>          </element-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CHC</term>
          <def>
            <p>chronic hepatitis C</p>
          </def>
        </def-item>
        <def-item>
          <term>GWAS</term>
          <def>
            <p>genome-wide association study</p>
          </def>
        </def-item>
        <def-item>
          <term>HCV</term>
          <def>
            <p>hepatitis C virus</p>
          </def>
        </def-item>
        <def-item>
          <term>
            <italic>HLA-C</italic>
          </term>
          <def>
            <p>human leukocyte antigen C</p>
          </def>
        </def-item>
        <def-item>
          <term>
            <italic>IL28B</italic>
          </term>
          <def>
            <p>interleukin 28B</p>
          </def>
        </def-item>
        <def-item>
          <term>
            <italic>KIR</italic>
          </term>
          <def>
            <p>killer immunoglobulin-like receptors</p>
          </def>
        </def-item>
        <def-item>
          <term>LR</term>
          <def>
            <p>likelihood ratio</p>
          </def>
        </def-item>
        <def-item>
          <term>NK</term>
          <def>
            <p>natural killer</p>
          </def>
        </def-item>
        <def-item>
          <term>NSVR</term>
          <def>
            <p>no sustained viral response</p>
          </def>
        </def-item>
        <def-item>
          <term>OR</term>
          <def>
            <p>odds ratio</p>
          </def>
        </def-item>
        <def-item>
          <term>PegIFN/R</term>
          <def>
            <p>pegylated interferon-alpha and ribavirin</p>
          </def>
        </def-item>
        <def-item>
          <term>SC</term>
          <def>
            <p>spontaneous clearer</p>
          </def>
        </def-item>
        <def-item>
          <term>SVR</term>
          <def>
            <p>sustained viral response</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    
  </back>
</article>